Genzyme lifted by EU approval of Fabrazyme facility
January 20, 2012Manufacturing and Production Boston, EMA, Fabrazyme, Genzyme
Sanofi subsidiary Genzyme moved a crucial step closer to resolving its long-standing manufacturing problems after the European Medicines Agency gave …
Payment changes of authority’s fees in France
January 20, 2012Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Wainwright Associates, regulatory affairs
Changes are being made in the way fees are paid for regulatory submissions and procedures in France. Fees are no …
Novartis’ Signifor recommended in Europe
January 20, 2012Research and Development, Sales and Marketing CHMP, Cushing's disease, Novartis, Signifor
A European committee has recommended Novartis’ Signifor for the treatment of a rare, debilitating endocrine disorder. The European Committee for …
EMA to review safety of MS drug Gilenya
January 20, 2012Research and Development, Sales and Marketing CHMP, EMA, Novartis, gilenya
The European Medicines Agency has begun a review into the safety of Novartis’ multiple sclerosis drug Gilenya. This follows concerns …
British pharmacy to sell ‘smart pills’
January 20, 2012Sales and Marketing Lloyds pharmacy, Proteus Biomedical, smart pill
Proteus Biomedical has teamed up with Lloydspharmacy to sell Helius, a smart pill that tells a patient when to take …
AZ and BMS diabetes drug needs more data
January 20, 2012Research and Development, Sales and Marketing AstraZeneca, BMS, FDA approvals, diabetes
AstraZeneca and Bristol-Myers Squibb must supply more data on their diabetes treatment dapagliflozin, the FDA says.Currently being developed as monotherapy, …
Novartis starts late-stage biosimilar trials for Amgen drugs
January 19, 2012Research and Development, Sales and Marketing Amgen, Neulasta, Neupogen, Novartis
Novartis has begun Phase III biosimilar trials to copycat two of Amgen’s neutropenia drugs. The studies, which are being undertaken …
Chief operating officer appointed to Clinigen’s services division
January 19, 2012Business Services, Medical Communications, Research and Development, Sales and Marketing Clinigen, Shaun Chilton
Clinigen Group, a global specialty pharma services and products business, has appointed Shaun Chilton as its new chief operating officer …
Takeda to cut 2,800 jobs
January 19, 2012Business Services, Research and Development, Sales and Marketing Nycomed, Takeda, job cuts
Takeda has announced plans to significantly reduce its global headcount over the next four years following its merger with Nycomed. …
Astellas Pharma Europe appoints Mike Crooks to head up its UK operations
January 19, 2012Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Astellas Pharma, Mike Crooks
Astellas Pharma Europe, the European subsidiary of Tokyo-based Astellas Pharma, has appointed Mike Crooks as its new UK general manager. …
Nurses come out against Health Bill
January 19, 2012Sales and Marketing NHS, RCN, health bill, reforms
The union representing nurses and midwives in the UK has formally come out against the government’s health reform Bill. The …
Bayer’s colorectal cancer drug increases survival
January 19, 2012Research and Development, Sales and Marketing Bayer, colectoral cancer, regorafenib
Bayer and Onyx’s colorectal cancer drug regorafenib increased overall survival for late-stage patients, according to new data. The Phase III …
Lucentis approved in China
January 18, 2012Sales and Marketing China, Galvus, Lucentis, Novartis, em, emerging markets
Novartis’ eye treatment Lucentis has gained approval in China, and the firm has also launched its diabetes drug Galvus in …
Lundbeck gets award for manufacturing excellence
January 18, 2012Manufacturing and Production Lundbeck, Shingo, manufacturing
Efforts by Lundbeck to boost the productivity of its manufacturing operations have borne fruit, with the company cutting costs by …
Former Bristol-Myers Squibb man becomes head of Savient Europe
January 18, 2012Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing BMS, Savient
Savient Pharmaceuticals has appointed David Veitch as the new president of its European division. Veitch joins the specialist biopharma firm …
Pfizer pulls plug on Alzheimer’s drug
January 18, 2012Research and Development, Sales and Marketing Medivation, Pfizer, dimebon
Pfizer and Medivation have written off their Alzheimer’s candidate dimebon after another Phase III failure. The firms said a 12-month …
Countdown to PM Society Advertising Awards begins
January 18, 2012Medical Communications, Sales and Marketing PM Society Advertising Awards, pm society
The Pharmaceutical Marketing Society’s Advertising Awards, one of the most significant dates in the UK pharma industry calendar, are approaching …
Novartis reverses plant closure decision
January 18, 2012Manufacturing and Production, Research and Development, Sales and Marketing Basel, Diovan, Novartis, Nyon, closure, job cuts
Novartis has said it will not close down a plant in Switzerland that had been due for closure, and has …
BMJ blasts Roche for withholding Tamiflu data
January 18, 2012Research and Development, Sales and Marketing BMJ, EMA, Roche, Tamiflu, WHO
Roche is still withholding Tamiflu data from researchers, claims the British Medical Journal. Two years after Roche said it would …
The work of NICE International
January 17, 2012Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Kalipso Chalkidou, NICE
NICE, or the National Institute for Health and Clinical Excellence, to give it its full title, is world famous for …
Latest content
Pharma sees climate disruption as growing supply-chain risk
Manchester NHS-MHRA partnership to test new technologies in real-world care
